Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation

Show full item record



Permalink

http://hdl.handle.net/10138/308171

Citation

Erkan , E P , Ströbel , T , Dorfer , C , Sonntagbauer , M , Weinhäusel , A , Saydam , N & Saydam , O 2019 , ' Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation ' , Frontiers in oncology , vol. 9 , 1031 . https://doi.org/10.3389/fonc.2019.01031

Title: Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation
Author: Erkan, Erdogan Pekcan; Ströbel, Thomas; Dorfer, Christian; Sonntagbauer, Markus; Weinhäusel, Andreas; Saydam, Nurten; Saydam, Okay
Contributor: University of Helsinki, Research Program in Systems Oncology
Date: 2019-10-10
Language: eng
Number of pages: 9
Belongs to series: Frontiers in oncology
ISSN: 2234-943X
URI: http://hdl.handle.net/10138/308171
Abstract: Meningiomas are primary central nervous system (CNS) tumors that originate from the arachnoid cells of the meninges. Recurrence occurs in higher grade meningiomas and a small subset of Grade I meningiomas with benign histology. Currently, there are no established circulating tumor markers which can be used for diagnostic and prognostic purposes in a non-invasive way for meningiomas. Here, we aimed to identify potential biomarkers of meningioma in patient sera. For this purpose, we collected preoperative (n = 30) serum samples from the meningioma patients classified as Grade I (n = 23), Grade II (n = 4), or Grade III (n = 3). We used a high-throughput, multiplex immunoassay cancer panel comprising of 92 cancer-related protein biomarkers to explore the serum protein profiles of meningioma patients. We detected 14 differentially expressed proteins in the sera of the Grade I meningioma patients in comparison to the age- and gender-matched control subjects (n = 12). Compared to the control group, Grade I meningioma patients showed increased serum levels of amphiregulin (AREG), CCL24, CD69, prolactin, EGF, HB-EGF, caspase-3, and decreased levels of VEGFD, TGF-α, E-Selectin, BAFF, IL-12, CCL9, and GH. For validation studies, we utilized an independent set of meningioma tumor tissue samples (Grade I, n = 20; Grade II, n = 10; Grade III, n = 6), and found that the expressions of amphiregulin and Caspase3 are significantly increased in all grades of meningiomas either at the transcriptional or protein level, respectively. In contrast, the gene expression of VEGF-D was significantly lower in Grade I meningioma tissue samples. Taken together, our study identifies a meningioma-specific protein signature in blood circulation of meningioma patients and highlights the importance of equilibrium between tumor-promoting factors and anti-tumor immunity.
Subject: 3122 Cancers
meningioma
proximity extension assay
biomarker
serum biomarker
CNS tumors
high-throughput immunoassay cancer panel
MYELOID CELLS
INTRACRANIAL MENINGIOMAS
CHEMOKINE RECEPTORS
CANCER
AMPHIREGULIN
RECURRENCE
SYSTEM
VEGF
AKT1
CD69
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fonc_09_01031.pdf 611.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record